Address
Email address
Phone number
https://chemi-pharm.comChemi-Pharm | Allergen-Free Disinfection ProductsChemi-Pharm AS develops, produces and sells allergen-free disinfection agents, cleansing and skincare products and detergents. Learn more!
Name
Lindenline OÜ
Registry code
11179976
VAT number
EE101911218
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
24.10.2005 (19)
Financial year
01.01-31.12
Capital
2 556.00 €
Activity
68201 - Rental and operating of own or leased real estate
575 084 €
240 345 €
42%
3 392 €
(estimate is approximate)
1 883 071 €
2
Submitted
No tax arrears
13%
5%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Ruth Oltjer 22.10.1959 (65) | 100% - 2 556.00 EUR | Board member | Direct ownership | |
| Hansaconsult OÜ 10560668 | - | - | - | Founder |
| 2019 14.02.2020 | 2020 19.02.2021 | 2021 27.05.2022 | 2022 15.03.2023 | 2023 17.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 449 904 € | 536 715 € | 556 967 € | 560 317 € | 575 084 € |
| Net profit (loss) for the period | 337 980 € | 266 394 € | 318 279 € | 655 701 € | 240 345 € |
| Profit Margin | 75% | 50% | 57% | 117% | 42% |
| Current Assets | 53 385 € | 200 041 € | 372 995 € | 150 580 € | 173 157 € |
| Fixed Assets | 3 809 220 € | 4 009 651 € | 3 916 883 € | 4 506 118 € | 4 446 319 € |
| Total Assets | 3 862 605 € | 4 209 692 € | 4 289 878 € | 4 656 698 € | 4 619 476 € |
| Current Liabilities | 248 732 € | 269 807 € | 382 830 € | 497 239 € | 2 191 165 € |
| Non Current Liabilities | 3 211 521 € | 3 271 139 € | 2 920 023 € | 2 516 733 € | 545 240 € |
| Total Liabilities | 3 460 253 € | 3 540 946 € | 3 302 853 € | 3 013 972 € | 2 736 405 € |
| Share Capital | - | - | - | - | - |
| Equity | 402 352 € | 668 746 € | 987 025 € | 1 642 726 € | 1 883 071 € |
| Employees | 2 | 3 | 2 | 2 | 2 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 186 192.32 € | 43 715.58 € | 12 347.4 € | 1 |
| 2023 Q4 | 162 285.92 € | 40 757.81 € | 12 347.4 € | 1 |
| 2023 Q3 | 153 795.4 € | 37 653.67 € | 12 347.4 € | 1 |
| 2023 Q2 | 157 030.28 € | 34 724.8 € | 8 525.4 € | 1 |
| 2023 Q1 | 732 024.47 € | 145 552.78 € | 6 614.4 € | 1 |
| 2022 Q4 | 167 503.03 € | - | 6 614.4 € | 1 |
| 2022 Q3 | 150 183.36 € | - | 6 614.4 € | 1 |
| 2022 Q2 | 163 848.62 € | 31 269.78 € | 6 614.4 € | 1 |
| 2022 Q1 | 167 785.92 € | 34 278.54 € | 6 614.4 € | 1 |
| 2021 Q4 | 153 968.63 € | 34 014.11 € | 6 614.4 € | 1 |
| 2021 Q3 | 145 399.01 € | 33 266.3 € | 6 614.4 € | 1 |
| 2021 Q2 | 148 563.81 € | 32 444.74 € | 6 614.4 € | 1 |
| 2021 Q1 | 184 118.88 € | 39 833.98 € | 6 614.4 € | 2 |
| 2020 Q4 | 138 427.42 € | 32 292.85 € | 7 368.6 € | 2 |
| 2020 Q3 | 131 559.65 € | 29 915.47 € | 7 334.64 € | 3 |
| 2020 Q2 | 134 220.73 € | 30 124.39 € | 7 334.64 € | 3 |
| 2020 Q1 | 143 290.34 € | 30 038.38 € | 6 767.4 € | 3 |
